Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
Renovorx Inc (RNXT) pioneers targeted therapeutic delivery systems designed to transform cancer treatment and vascular interventions through its proprietary Trans-Arterial Micro-Perfusion technology. This page serves as the definitive source for verified updates about the clinical-stage innovator’s progress in precision medicine.
Investors and medical professionals will find comprehensive coverage of FDA clearances, clinical trial milestones, and strategic partnerships. Track developments in RNXT’s pipeline including oncology-focused device innovations and evidence-based research validating its Renovocath™ delivery platform.
Key updates include regulatory submissions, peer-reviewed study results, manufacturing collaborations, and financial performance reports. All content is curated to support informed analysis of RNXT’s position in the competitive medical device sector while adhering to strict journalistic standards.
Bookmark this page for streamlined access to essential RNXT developments. Combine our real-time updates with Stock Titan’s financial tools to monitor this innovator in localized therapeutic delivery systems.
RenovoRx (Nasdaq: RNXT) announced that CEO Shaun Bagai will present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20, 2025 at 2:00 PM ET.
He will review commercial progress for RenovoCath, report year-to-date revenue of approximately $900,000 (as of Sept 30, 2025), and summarize clinical programs including the ongoing Phase III TIGeR-PaC trial for intra-arterial gemcitabine in locally advanced pancreatic cancer, a post-marketing registry capturing real-world safety and effectiveness data, and investigator-initiated studies in borderline resectable and oligometastatic pancreatic cancer. The presentation will cover adoption trends, market traction, and the TAMP therapy platform. Webcast access is provided on the company's investor relations site.
RenovoRx (Nasdaq: RNXT) reported third-quarter 2025 results on November 13, 2025, highlighting early commercial traction for its FDA-cleared RenovoCath device and progress on its Phase III TIGeR-PaC trial.
Key figures: Q3 revenue $266,000, year-to-date revenue ~$900,000, cash $10.0 million as of September 30, 2025, and Q3 net loss $2.9 million. The company expanded approved RenovoCath customers from five to 14 centers in 2025 and expects TIGeR-PaC enrollment to complete in early 2026 with final data in 2027.
RenovoRx (Nasdaq: RNXT) announced the appointment of Timothy Donahue, MD, a UCLA pancreatic surgery and translational oncology expert, to its Scientific Advisory Board on November 6, 2025. Dr. Donahue is Director of UCLA’s Agi Hirshberg Center for Pancreatic Diseases, Chief of the Division of Surgical Oncology, holds the Garry Shandling Chair in Pancreatic Surgery, and leads an NIH-funded research laboratory.
He performs high-volume pancreatic surgery, directs integrated induction-plus-surgery programs for locally advanced and borderline resectable pancreatic cancer, and endorsed RenovoRx’s targeted delivery platform, Trans-Arterial Micro-Perfusion (TAMP™).
RenovoRx (Nasdaq: RNXT) announced that CEO Shaun Bagai will participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20, 2025 in New York.
Mr. Bagai will provide an update on RenovoCath commercialization, discuss latest developments from the ongoing Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine delivered via RenovoCath for locally advanced pancreatic cancer, and review a recently launched post-marketing observational registry tracking long-term safety and survival outcomes for patients treated with RenovoCath.
RenovoRx (Nasdaq: RNXT) will host its Q3 2025 financial results and business highlights conference call on November 13, 2025 at 4:30 p.m. ET. Management is expected to discuss RenovoCath commercialization, progress in the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, and the PanTheR Post‑Marketing Registry Study evaluating long‑term safety and survival for patients treated with RenovoCath.
Investors can join by phone (1-877-407-4018 U.S. or 1-201-689-8471 international) or via webcast at https://ir.renovorx.com/news-events/ir-calendar-events. A Q&A will follow the presentation. A dial‑in replay is available through November 27, 2025 (1-844-512-2921 U.S. or 1-412-317-6671 international; replay PIN 13756201), and the recording will be posted on the investor relations website.
RenovoRx (Nasdaq: RNXT) announced on October 9, 2025 the appointment of Thierry de Baère, MD, PhD, to its Scientific Advisory Board.
Professor de Baère is Head of Interventional Radiology at Gustave Roussy and University Paris-Saclay, has over 400 peer-reviewed publications and >22,000 citations, and brings expertise in ablation, intra-tumoral immunotherapy, intra-arterial chemotherapy and locoregional cancer therapies.
The company said his experience is directly relevant to its Trans-Arterial Micro-Perfusion (TAMP™) therapy platform enabled by the FDA-cleared RenovoCath device and will support clinical development and commercial exploration.
RenovoRx (NASDAQ:RNXT) announced significant progress in its PanTheR Post-Marketing Registry Study for the FDA-cleared RenovoCath drug-delivery device. The first patient procedure was successfully completed at the University of Vermont Cancer Center, and two additional clinical sites - Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center - have joined the registry study.
The PanTheR study (NCT06805461) aims to gather expanded safety and performance data of RenovoCath and its survival outcomes in patients with solid tumors. The study is led by Principal Investigators Dr. Ripal Gandhi, Dr. Paula Novelli, and Dr. Conor O'Neill at their respective institutions. This real-world data collection will help guide future treatment decisions and enhance safety protocols for cancer patients.
RenovoRx (Nasdaq: RNXT), a life sciences company focused on targeted oncology therapies, announced CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Fall Investment Conference on September 16, 2025, at 12:30 PM ET.
The presentation will cover RenovoRx's commercialization of RenovoCath, their FDA-cleared drug-delivery device, and provide updates on their Phase III TIGeR-PaC clinical trial. The trial, which recently passed its second interim analysis after the 52nd death, is evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath for locally advanced pancreatic cancer (LAPC) treatment.
RenovoRx (Nasdaq: RNXT), a life sciences company focused on targeted oncology therapies, announced CEO Shaun Bagai will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025.
The presentation will cover RenovoCath's commercialization progress, including organic revenue growth driven by market demand for this FDA-cleared drug-delivery device. Additionally, Bagai will discuss updates on the Phase III TIGeR-PaC clinical trial, which recently received approval to continue following the Data Monitoring Committee's review of the second interim analysis after the 52nd death. The trial evaluates intra-arterial gemcitabine (IAG) delivered via RenovoCath for locally advanced pancreatic cancer treatment.
RenovoRx (Nasdaq: RNXT) reported strong Q2 2025 results, with RenovoCath® device revenue reaching $422,000. The company's independent Data Monitoring Committee (DMC) recommended continuing the pivotal Phase III TIGeR-PaC trial following a positive interim data review. As of June 30, 2025, RenovoRx had $12.3 million in cash, with 95 patients randomized and 61 events recorded in the trial.
The company has expanded its RenovoCath commercialization, with thirteen cancer center customers approved for device purchase, up from five in Q1 2025. Four centers have used the device with repeat orders. RenovoRx estimates an initial $400 million peak annual U.S. sales opportunity for RenovoCath as a standalone device, with potential for multi-billion-dollar TAM through additional applications.
Financial results showed a net loss of $2.9 million for Q2 2025, compared to $2.4 million in Q2 2024. R&D expenses decreased to $1.4 million from $1.5 million year-over-year, while SG&A expenses remained stable at $1.5 million.
FAQ
What is the current stock price of Renovorx (RNXT)?
What is the market cap of Renovorx (RNXT)?
